Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity.
Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The company will release initial data from that study later this year and said it is working with regulators to plan a late-stage trial. Amgen is planning a stage-two trial on the drug in diabetes treatment, as well.
The company's experimental injection helps people lose weight differently from the existing injectable drugs. Much like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, one part of Amgen's treatment activates a gut hormone receptor called GLP-1 to help regulate a person's appetite. Patients given the highest dose of Amgen's MariTide — 420 milligrams — every month lost 14.5% of their body weight on average in just 12 weeks, according toAlso on Thursday, Amgen reported first-quarter revenue and adjusted earnings that topped Wall Street's expectations, partly thanks to products from the recently acquired Horizon Therapeutics.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amgen scraps experimental weight loss pill, moves forward with injectionAmgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Read more »
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicThe agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Read more »
FTC challenges ‘junk' patents held by 10 drugmakers, including for Novo Nordisk's OzempicThe agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
Read more »
Novo Nordisk trims price for blockbuster obesity drug as competition heats upNovo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while competition from rival Eli Lilly forced the company to cut prices of the drug, knocking its shares.
Read more »
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortagesNovo Nordisk's Negelle Morris spoke exclusively with ABC News.
Read more »